A modified GHRH analog designed to last longer than natural GHRH. It is not approved and has no 503A pathway.
Key takeaway
CJC-1295 is a GHRH analog engineered to resist breakdown. The “with DAC” version binds to albumin in the blood to extend how long it lasts.
At a glance
| FDA status | Not FDA-approved |
|---|---|
| 503A compounding | No 503A pathway: nomination withdrawn after FDA safety review |
| Body areas | Hormones & pituitary, Muscle, joints & recovery |
| Through ScriptMates | Information only |
| Open questions | None noted |
What is CJC-1295?
CJC-1295 is a GHRH analog engineered to resist breakdown. The “with DAC” version binds to albumin in the blood to extend how long it lasts.
FDA has identified serious adverse events associated with CJC-1295 and has concerns about immunogenicity and impurities in compounded versions.
Dosage forms
No FDA-approved dosage form. A standardized dosage form for human use was not confirmed from the sources below.
Is CJC-1295 FDA-approved?
Not FDA-approved. CJC-1295 was nominated for the 503A bulks list and placed in Category 2 over safety concerns; the nomination was later withdrawn. FDA notes it has no, or only limited, safety information for the proposed uses.
Can it be prescribed through ScriptMates?
No 503A pathway: nomination withdrawn after FDA safety review. A partner pharmacy lists it, but it has no lawful 503A pathway today (nomination withdrawn after FDA safety review).
Sources
- FDA: Bulk substances that may present significant safety risks (Category 2 and withdrawn nominations)
- FDA: Bulk drug substances nominated under 503A, Categories 1–3 (May 14, 2026)
Checked October 27, 2026. FDA updates these pages, so confirm before relying on them.